Investors in Amicus Therapeutics (NASDAQ:FOLD) From a Year Ago Are Still Down 19%, Even After 3.9% Gain This Past Week
Amicus Therapeutics(FOLD.US) Officer Sells US$75,000 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 7,500 shares of common stock on Jun 3, 2024 at an average price of $10 for a total value of $75,000.Source: Announcement What is statemen
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti (Cipaglucosidase Alfa) + Opfolda (Miglustat) as Best Pharmaceutical Product
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today
It's Unlikely That Shareholders Will Increase Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Compensation By Much This Year
Key Insights Amicus Therapeutics will host its Annual General Meeting on 6th of June CEO Brad Campbell's total compensation includes salary of US$698.6k Total compensation is similar to the indust
Express News | Amicus Therapeutics Inc : Wells Fargo Initiates Coverage With Overweight Rating; Target Price $18
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) Are in the Red If They Invested Five Years Ago
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some selections. So we wouldn't blame long term Amicus Therapeutics, Inc. (NASDAQ:FO
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Express News | Amicus Therapeutics Inc : JP Morgan Cuts Target Price to $17 From $19
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below provides a snapsh
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies a
Express News | Amicus Therapeutics Shares Are Trading Higher After Guggenheim Upgraded the Stock From Neutral to Buy and Announced a $13 Price Target
Express News | Guggenheim Upgrades Amicus Therapeutics to Buy, Announces $13 Price Target
Express News | Amicus Therapeutics Inc : Guggenheim Raises to Buy From Neutral
Amicus Therapeutics Is Maintained at Buy by UBS
Amicus Therapeutics Is Maintained at Buy by UBS
Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...
Express News | Amicus Therapeutics Inc : UBS Cuts Target Price to $19 From $20
Amicus Therapeutics Is Maintained at Buy by B of A Securities
Amicus Therapeutics Is Maintained at Buy by B of A Securities
Express News | B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13
Express News | Needham Reiterates Hold on Amicus Therapeutics
No Data